Evidence map›Paper›PMID 27823883›Full record

ArticleEuropean journal of medicinal chemistry2017

Oligonucleotide transition state analogues of saporin L3.

Jennifer M Mason, Hongling Yuan, Gary B Evans, Peter C Tyler, Quan Du, Vern L Schramm

Abstract read
In one paragraph

Article in European journal of medicinal chemistry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jennifer M MasonThe Ferrier Institute, Victoria University of Wellington, 69 Gracefield Rd, Lower Hutt 5010, New Zealand. Electronic address: jennifer.mason@vuw.ac.nz.
Hongling YuanDepartment of Biochemistry, Albert Einstein College of Medicine, 1300 Morris Park Ave., Bronx, NY 10461, USA.
Gary B EvansThe Ferrier Institute, Victoria University of Wellington, 69 Gracefield Rd, Lower Hutt 5010, New Zealand.
Peter C TylerThe Ferrier Institute, Victoria University of Wellington, 69 Gracefield Rd, Lower Hutt 5010, New Zealand.
Quan DuDepartment of Biochemistry, Albert Einstein College of Medicine, 1300 Morris Park Ave., Bronx, NY 10461, USA.
Vern L SchrammDepartment of Biochemistry, Albert Einstein College of Medicine, 1300 Morris Park Ave., Bronx, NY 10461, USA.

Funding

WORD PROCESSORP30CA013330 · NCI · YESHIVA UNIVERSITY · PI STEVEN C. ALMO · 1985 to 2026
$111.2M
TRANSITION STATE ANALYSIS OF ENZYMATIC REACTIONSR01GM041916 · NIGMS · YESHIVA UNIVERSITY · PI SCHRAMM, VERN L. · 1989 to 2023
$10.0M
RICIN--MECHANISM, TRANSITION STATE AND INHIBITOR DESIGNR01CA072444 · NCI · YESHIVA UNIVERSITY · PI SCHRAMM, VERN L. · 1997 to 2011
$4.4M
TRANSITION STATE ANALYSIS OF ENZYMATIC REACTIONSR37GM041916 · NIGMS · YESHIVA UNIVERSITY · PI SCHRAMM, VERN L. · 1998 to 2007
$3.5M
NCI NIH HHS P30 CA013330NCI NIH HHS R01 CA072444NIGMS NIH HHS R01 GM041916NIGMS NIH HHS R37 GM041916
6 · The paper itself

Abstract

Ribosome inactivating proteins (RIPs) are among the most toxic agents known. More than a dozen clinical trials against refractory cancers have been initiated using modified RIPs with impressive results. However, dose-limiting toxicity due to vascular leak syndrome limits success of the therapy. We have previously reported some tight-binding transition state analogues of Saporin L3 that mimic small oligonucleotide substrates in which the susceptible adenosine has been replaced by a 9-deazaadenyl hydroxypyrrolidinol derivative. They provide the first step in the development of rescue agents to prevent Saporin L3 toxicity on non-targeted cells. Here we report the synthesis, using solution phase chemistry, of these and a larger group of transition state analogues. They were tested for inhibition against Saporin L3 giving K

Indexed as

Base SequenceBiomimetic MaterialsModels, MolecularOligonucleotidesProtein ConformationRibosome Inactivating Proteins, Type 1RNASaporinsOligonucleotidesRibosome Inactivating Proteins, Type 1RNASaporinsAza-sugarOligonucleotideRibosome inactivating proteinSaporinTransition state inhibitor

Identifiers

PMID27823883
PMCPMC5296225

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.